Treatment Advances
Nivolumab Plus Ipilimumab Remains First-Line Standard for Unresectable Mesothelioma
The combination of nivolumab and ipilimumab (Opdivo + Yervoy) continues to demonstrate superior overall survival compared to chemotherapy for...
FDA approvals, new therapies, clinical trial results, and emerging mesothelioma treatments.
The combination of nivolumab and ipilimumab (Opdivo + Yervoy) continues to demonstrate superior overall survival compared to chemotherapy for...
Tumor Treating Fields (TTFields), a wearable medical device that uses alternating electric fields to disrupt cancer cell division, has demonstrated a...